NVO•benzinga•May 7, 2025 at 06:48 AM

Novo Nordisk Lowers 2025 Outlook: Sales Growth Now Seen At 13–21% (Prior 16%–24%) At CER and Operating Profit at 16–24% (Priro 19%–27%) At CER, Citing Weaker Branded GLP-1 Uptake Amid Rapid US Compounding Expansion

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 7, 2025 by benzinga